Ick Chan Kwon Selected Research

Paclitaxel (Taxol)

12/2013	Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
2/2012	Enhancement of the targeting capabilities of the Paclitaxel-loaded pluronic nanoparticles with a glycol chitosan/heparin composite.
12/2010	Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy.
9/2010	Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring.
12/2007	Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation.
3/2006	Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel.
2/2005	Stable paclitaxel formulations in oily contrast medium.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ick Chan Kwon Research Topics

Disease

179	Neoplasms (Cancer) 04/2024 - 08/2003
12	Breast Neoplasms (Breast Cancer) 11/2017 - 05/2008
9	Melanoma (Melanoma, Malignant) 03/2024 - 02/2005
8	Thrombosis (Thrombus) 01/2021 - 12/2011
8	Atherosclerosis 01/2020 - 10/2008
6	Rheumatoid Arthritis 06/2019 - 11/2008
5	Stroke (Strokes) 01/2021 - 05/2013
5	Atherosclerotic Plaque (Atheroma) 10/2018 - 06/2008
5	Inflammation (Inflammations) 01/2017 - 03/2010
4	Neoplasm Metastasis (Metastasis) 07/2022 - 05/2008
4	Arthritis (Polyarthritis) 06/2019 - 12/2011
4	Colonic Neoplasms (Colon Cancer) 09/2012 - 12/2009
4	Osteoarthritis 01/2012 - 09/2008
3	Wounds and Injuries (Trauma) 01/2020 - 11/2018
3	Carcinogenesis 01/2020 - 12/2010
3	Cardiotoxicity 01/2019 - 12/2010
3	Infections 01/2018 - 06/2005
3	Infarction (Infarctions) 01/2018 - 12/2016
3	Hemorrhage 01/2017 - 05/2008
3	Ischemia 12/2016 - 09/2013
3	Experimental Arthritis 10/2015 - 12/2011
2	Communicable Diseases (Infectious Diseases) 01/2024 - 01/2018
2	Prostatic Neoplasms (Prostate Cancer) 11/2019 - 01/2017

Drug/Important Bio-Agent (IBA)

47	glycol-chitosanIBA 03/2023 - 08/2003
32	Small Interfering RNA (siRNA)IBA 04/2024 - 09/2009
27	Peptides (Polypeptides)IBA 01/2024 - 03/2004
21	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2022 - 08/2003
16	Hyaluronic Acid (Hyaluronan)IBA 11/2018 - 01/2010
15	MicellesIBA 03/2023 - 11/2007
15	Matrix Metalloproteinases (MMPs)IBA 01/2016 - 09/2008
13	PolymersIBA 03/2023 - 02/2007
13	Drug CarriersIBA 07/2022 - 04/2008
13	LigandsIBA 12/2017 - 08/2008
12	Proteins (Proteins, Gene)FDA Link 04/2024 - 07/2010
12	Photosensitizing Agents (Photosensitizers)IBA 12/2019 - 05/2009
12	GoldIBA 01/2018 - 12/2010
11	Coloring Agents (Dyes)IBA 01/2017 - 12/2009
10	Poloxamer (Poloxamer 407)IBA 10/2018 - 05/2010
9	1-phenyl-3,3-dimethyltriazene (PDT)IBA 12/2019 - 01/2011
7	Therapeutic UsesIBA 01/2018 - 05/2008
7	Liposomes (Liposome)IBA 12/2017 - 12/2009
7	Docetaxel (Taxotere)FDA Link 10/2016 - 05/2008
7	CY5.5 cyanine dyeIBA 01/2016 - 10/2007
7	Heparin (Liquaemin)FDA LinkGeneric 12/2014 - 05/2008
7	Paclitaxel (Taxol)FDA LinkGeneric 12/2013 - 02/2005
7	ChitosanIBA 05/2012 - 08/2003
6	Singlet OxygenIBA 12/2019 - 01/2011
5	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 03/2013
5	VaccinesIBA 03/2024 - 03/2002
5	ProdrugsIBA 12/2020 - 02/2015
5	CollagenIBA 01/2020 - 09/2012
5	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 05/2009
5	HydrogelsIBA 11/2018 - 02/2007
4	AntigensIBA 01/2024 - 02/2015
4	EnzymesIBA 10/2020 - 12/2009
4	Caspase 3 (Caspase-3)IBA 12/2019 - 02/2015
4	Cathepsin BIBA 01/2019 - 01/2012
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2017 - 12/2015
4	AzidesIBA 12/2017 - 03/2014
4	IntegrinsIBA 01/2017 - 12/2012
4	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2017 - 05/2013
4	Contrast MediaIBA 05/2016 - 01/2014
4	Ethylene Glycol (Monoethylene Glycol)IBA 06/2013 - 08/2008
4	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 11/2011 - 05/2008
3	AntibodiesIBA 04/2024 - 08/2008
3	PolyethyleneimineIBA 01/2020 - 06/2010
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 10/2016
3	Oxygen (Dioxygen)IBA 12/2019 - 07/2013
3	CytokinesIBA 10/2019 - 02/2014
3	Biocompatible Materials (Biomaterials)IBA 01/2019 - 08/2011
3	Polysaccharides (Glycans)IBA 01/2017 - 11/2016
3	Dextran SulfateIBA 01/2017 - 01/2014
3	AcidsIBA 01/2017 - 06/2010
3	CaspasesIBA 01/2016 - 02/2011
3	DisulfidesIBA 11/2014 - 10/2011
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2014 - 11/2008
3	CeramidesIBA 01/2014 - 10/2011
3	Peptide Hydrolases (Proteases)FDA Link 01/2012 - 03/2010
3	Fluorescein-5-isothiocyanate (FITC)IBA 10/2011 - 08/2003
3	protoporphyrin IXIBA 06/2011 - 05/2009
3	poly(lactide) (polylactic acid)IBA 06/2010 - 08/2008
3	poly(beta-amino ester)IBA 06/2010 - 11/2007
3	monomethoxypolyethylene glycol (MPEG)IBA 06/2010 - 11/2007
3	EmulsionsIBA 10/2006 - 02/2005
2	Glucose (Dextrose)FDA LinkGeneric 03/2023 - 01/2017
2	OvalbuminIBA 10/2021 - 02/2015
2	ErbB Receptors (EGF Receptor)IBA 12/2020 - 12/2013
2	Epidermal Growth Factor (EGF)IBA 12/2020 - 12/2013
2	Lysine (L-Lysine)FDA Link 11/2019 - 08/2014

Therapy/Procedure

86	Therapeutics 04/2024 - 02/2007
16	Precision Medicine 12/2020 - 04/2011
13	Intravenous Injections 10/2020 - 02/2007
11	Photochemotherapy (Photodynamic Therapy) 12/2019 - 08/2010
10	Drug Therapy (Chemotherapy) 12/2017 - 02/2007
8	Immunotherapy 04/2024 - 02/2015
8	Intravenous Administration 02/2016 - 01/2006
5	Lasers (Laser) 07/2015 - 06/2010
4	Photothermal Therapy 01/2017 - 12/2010
3	RNAi Therapeutics 11/2022 - 08/2014
3	Urinary Catheters 01/2003 - 10/2002